Bavarian Nordic has extensive experience in the research, development and production of vaccines for infectious diseases and cancer, and operates a commercial scale manufacturing facility. The facility is currently being expanded with a fill and finish plant, thus enabling Bavarian Nordic to take full control of the product cycle.

We have a strong intellectual property position with our MVA-BN® technology and other poxvirus-based technologies. We also have a successful track record working with the U.S. government and have built relationships with other governments around the world, in addition to several commercial partnerships.

We are seeking partners, both governmental and commercial, for mutually beneficial collaborations to strengthen our MVA-BN technology or pipeline of infectious diseases and cancer immunotherapy candidates. We also offer out-licensing opportunities of our proprietary technologies and vaccine programs, as well as contract development and manufacturing (CDMO).

For more information on our CDMO services, please visit:


If you want to get in touch with our business development team, please send an e-mail to

Our Partners

Janssen License and supply agreement for MVA-BN Filo for Ebola vaccine

BARDA Development and procurement of MVA-BN smallpox vaccine

NIH Early development of MVA-BN smallpox vaccine and MVA-BN Filo for Ebola and Marburg viruses

DHS Early development of MVA-BN for foot-and-mouth disease virus